Compare the Safety and Effectiveness of Two Different Kinds of Stent System in Intracranial Aneurysms

Exclusion Criteria

• •1. Target aneurysm is an aneurysm requiring staged procedure.
• •2. Target aneurysm that has been previously treated with vascular embolization or surgery.
• •3. Target aneurysms are fusiform aneurysms, dissecting aneurysms, pseudoaneurysms, blood blister-like aneurysms, infected aneurysms, aneurysms associated with arteriovenous malformations.
• •4. Hospitalized surgical treatment within 30 days before operation, or planned hospitalized surgical treatment within 6 months after surgery.
• •5. Acutely ruptured aneurysm within 14 days of enrollment.
• •6. Hunt and Hess (H\&H) scale ≥3.
• •7. Subject who had Moyamoya disease, arteriovenous malformations, arteriovenous fistulae, intracranial tumors, or intracranial mass lated to target aneurysms.
• •8. Severe stenosis or tortuosity of intracranial arteries or anatomical anomalies that make it difficult to reach the site of the lesion with device.
• •9. Platelet count \<50\*103/mm3 (50\*109/L) or any known coagulation deficiency, or International normalized ratio (INR)\>3.0.
• •10. Known hypersensitivity/allergies or contraindication to contrast media, stent components, antiplatelets, anticoagulants.
• •11. Life expectancy \< 1 year, and unable to complete the required follow-ups;
• •12. Female who was pregnant or breastfeeding, women/men planning to havve children in the next year.
• •13. Currently enrolled in another investigational device or drug study.